IOVANCE (IOVA) Interim CEO Frederick Vogt Receives 41,669 Shares

What Happened

• Frederick G. Vogt, Interim CEO & General Counsel and a director of Iovance Biotherapeutics (IOVA), had 41,669 restricted stock units (RSUs) convert to common stock (reported as derivative exercises) on September 1, 2026. The RSU vesting generated 41,669 shares (exercise/conversion code M @ $0.00). To satisfy mandatory tax withholding, 17,702 of those shares were withheld by the issuer (code F) at an implied value of $8.28 per share, totaling $146,573. After withholding, Vogt received 23,967 net shares.

Key Details

• Transaction date: 2026-09-01; Form filed: 2026-09-03 (appears timely).
• Derivative conversion (M): 41,669 RSUs converted to common stock @ $0.00 (acquired).
• Tax withholding (F): 17,702 shares withheld @ $8.28 = $146,573 (disposed for tax withholding; not an open-market sale).
• Net shares delivered to insider: 23,967 common shares after withholding.
• Relevant footnotes: RSUs vested on the transaction date; each RSU equals one share; withheld shares satisfy mandatory taxes and are not an open market sale; remaining RSUs from the March 1, 2024 grant will vest in equal quarterly installments.

Context

• This filing reflects an award vesting (receipt of shares), not a market purchase or discretionary sale. The tax withholding is a standard settlement method (issuer withholding) and should not be interpreted as an open-market sale signal. The reporting simply documents conversion of RSUs into shares and the mandatory tax withholding.